 PHILADELPHIA, July 29, 2021 PRNewswire -- Lannett Company, Inc. NYSE: LCI today announced that it has entered into an exclusive U.S. commercialization agreement for a therapeutically equivalent generic of Spiriva Handihaler Tiotropium Bromide inhalation powder with Respirent Pharmaceuticals Co. Ltd. The 10-year term of the agreement commences upon distribution of the product. 